IDEAYA Biosciences Quarterly Income Statement
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEAYA Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, IDEAYA Biosciences generated $8.9 million in revenue. IDEAYA Biosciences reported a net loss of $112.5 million, compared with a loss of $77.5 million a year earlier. Operating margin was -1380.7%.
Diluted earnings per share came in at -$1.22.
Summary generated from market data by MetaCap's automated system. Methodology
IDEAYA Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.86M | 6.56M | 10.88M | 207.83M | — | — | 7.00M | 0 | 0 | 0 | 3.92M | 8.04M |
| Revenue growth (YoY) | — | — | +55.37% | — | — | — | +78.48% | -100.00% | -100.00% | -100.00% | -2.49% | -72.94% |
| Operating Expenses | 131.15M | 115.10M | 105.45M | 99.38M | 88.81M | 84.39M | 151.14M | 66.89M | 64.93M | 51.02M | 45.84M | 41.56M |
| Research & Development | 108.69M | 95.73M | 86.60M | 82.99M | 74.23M | 70.89M | 140.18M | 57.15M | 54.53M | 42.80M | 38.77M | 33.70M |
| Operating Income | -122.29M | -108.54M | -94.57M | 108.45M | -88.81M | -84.39M | -144.14M | -66.89M | -64.93M | -51.02M | -41.92M | -33.53M |
| Other Income (Expense) | 9.84M | 10.01M | 11.30M | 10.79M | 11.31M | 12.21M | 13.83M | 15.07M | 12.15M | 11.45M | 7.96M | 6.09M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -112.45M | -98.54M | -83.27M | 119.24M | -77.49M | -72.18M | -130.31M | -51.82M | -52.77M | -39.57M | -33.95M | -27.44M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | -1799.07% |
| EPS (Basic) | -1.22 | -1.11 | -0.93 | 1.35 | -0.88 | -0.82 | -1.55 | -0.60 | -0.68 | -0.53 | -0.51 | -0.46 |
| EPS (Diluted) | -1.22 | -1.11 | -0.91 | 1.33 | -0.88 | -0.82 | -1.55 | -0.60 | -0.68 | -0.53 | -0.51 | -0.46 |
| Shares Outstanding (Basic) | 92.06M | 88.70M | — | 88.53M | 88.47M | 88.36M | — | 86.19M | 77.96M | 75.11M | — | 60.00M |
| Shares Outstanding (Diluted) | 92.06M | 88.70M | — | 89.69M | 88.47M | 88.36M | — | 86.19M | 77.96M | 75.11M | — | 60.00M |
| EBITDA | -121.60M | -107.86M | -93.85M | 109.11M | -88.09M | -83.79M | -143.57M | -66.32M | -64.31M | -50.40M | -41.29M | -32.89M |
| Operating Margin | -1380.73% | -1654.63% | -869.53% | 52.18% | — | — | -2059.11% | — | — | — | -1068.77% | -417.09% |
| Net Margin | -1269.64% | -1502.12% | -765.66% | 57.37% | — | — | -1861.60% | — | — | — | -865.76% | -341.38% |
This table shows 12 quarterly periods of IDEAYA Biosciences's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow IDYA's reporting calendar. What is a income statement?